Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8912585 | 0.85 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8569459 | 0.84 | EPHX2 (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8564005 | 0.83 | ADRA1D (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL261805 | 0.80 | HDAC3 (0.72) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8567882 | 0.80 | HDAC3 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL260966 | 0.80 | HDAC3 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8569268 | 0.78 | ADRA1D (0.70) | ADRA1DKCNH2ADRA1A | |
| SCHEMBL8565539 | 0.78 | KCNH2 (0.68) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8913667 | 0.78 | KCNH2 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL267585 | 0.78 | ADRA1D (0.56) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2255201-B1 | FLUORESCENCE POLARIZATION HERG ASSAY | LIFE TECHNOLOGIES CORP (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2255201-B1 | FLUORESCENCE POLARIZATION HERG ASSAY | LIFE TECHNOLOGIES CORP (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20120231541-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120231541-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2012-09-13 | — | — | US | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133695-B2 | Fluorescence polarization hERG assay | Life Technologies Corporation (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2255201-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | Life Technologies Corporation (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009108905-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108905-A2 | FLUORESCENCE POLARIZATION HERG ASSAY | Life Technologies Corporation (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-0431943-B1 | Spiro(pyran)piperidine derivatives | MERCK & CO INC (US) | 1998-07-15 | — | — | EP | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253148-A1 | FLUORESCENCE POLARIZATION hERG ASSAY | TNNI3, TNNT2, KCNQ1 | HDAC3 1683/4885HDAC4 3049/4885HDAC1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.